(RTTNews) - GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY when co ...

His analysis indicates skepticism towards the company’s U.S. market share for its RSV vaccine, Arexvy, which has been dropping. Despite efforts to maintain pricing, the entry of other market ...

Arexvy is a brand-name respiratory syncytial virus (RSV) vaccine. It’s used in some adults to help prevent lung disease from RSV. Arexvy should not be used during pregnancy and breastfeeding ...

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has ...

Findings showed a noninferior immune response for both vaccines when coadministered compared with separate administration. Topline results were announced from a phase 3 study assessing the immune ...

AREXVY is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older, as well as individuals 50 ...

2 SHINGRIX is approved for the prevention of shingles (herpes zoster) in adults aged 50 years and older. AREXVY is approved for the prevention of lower respiratory tract disease (LRTD) caused by ...

The company studied co-administration of its RSV vaccine Arexvy and Shingrix in a phase 3 study of 530 adults age 50 years and older. When the shots were given during the same doctor's visit ...

There are no data on the use of AREXVY in pregnant or breastfeeding individuals. AREXVY is not approved for use in persons <50 years of age. Vaccination with AREXVY may not result in protection of all ...